• Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • About
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Advertise
PharmaLive
  • Marketing & Advertising
  • R&D
  • Therapeutics
  • Resources
  • Manny Awards
  • Events
  • Issue Archives
  • Subscribe
  • Search
  • Menu

Janssen recruiting for Phase III trials of potential myasthenia gravis game changer

R&D

Janssen recruiting for Phase III trials of potential myasthenia gravis game changer

Published: Jun 20, 2022

By Gail Dutton

BioSpace

June is Myasthenia Gravis Awareness month.

As with so many rare diseases, the standard of care for myasthenia gravis (MG) doesn’t address the root of the illness and comes with side effects that can be serious. Nipocalimab, which is in Phase III development at Janssen, goes to the cause of the disease.

Myasthenia gravis is an autoantibody-driven disease in which the body generates antibodies against its own proteins. In this case, the antibodies target the acetylcholine receptor (AChR) or a muscle-specific kinase (MuSK) receptor on cells. “These autoantibodies attack the neuromuscular junction, which is the interface where the nerve signals communicate with muscle,” Fiona Elwood, Ph.D., VP, disease area leader, neurodegeneration at Janssen Research & Development, said in an interview with BioSpace.

“When that breaks down, MG patients suffer muscle-related symptoms like muscle weakness.” It affects approximately 700,000 people throughout the world. Between 15 and 20 percent of them may be hospitalized with the disease, which manifests as difficulty with movements, drooping eyelids and even breathing difficulties. “It’s a rare, and pretty nasty disease,” she said.

Michael Vi/Shutterstock

Janssen’s solution, nipocalimab, is an anti-neonatal Fc receptor (FcRn) monoclonal antibody that blocks FcRn and lowers IgG (which, in autoantibody diseases, helps destroy red blood cells prematurely). Its application to MG stems from its ability to cause autoantibodies to be cleared from the body.

As Elwood explained, “Antibodies have quite a long half-life because they can be recycled through cells and hidden from the clearance process. By targeting the FcRn, which is responsible for cycling and hiding antibodies themselves, nipocalimab blocks that response and, instead, directs them to be degraded and cleared from the body. Therefore, you flush out all the IgG antibodies in the body and so flush out all of those targeted autoantibodies. In the case of MG, that’s AChR or MuSK.”

Because nipocalimab targets autoantibodies, “It may be used across multiple different neurological and immunological diseases in which the autoantibody to the self-protein is causing the disease,” she said. Chronic inflammatory demyelinating polyneuropathy (CIPD) is one likely indication, as well as other autoimmune diseases in the areas of maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. “We believe nipocalimab can have a really significant impact,” Elwood said.

“Phase II results showed robust, rapid, lowering of autoantibodies and strong duration,” she noted. That data, presented at a scientific meeting last year, compared the results of standard-of-care treatment plus either nipocalimab or placebo in 68 patients. The primary endpoint was to identify changes in patients’ Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. Secondary endpoints included changes in patients’ Quantitative Myasthenia Gravis (QMG) score, the revised Myasthenia Gravis Quality of Life 15-item (MG-QoL15) scale and nipocalimab’s pharmacokinetic and pharmacodynamic activity.

A global, Phase III trial is recruiting now for adults with MG. In it, nipocalimab will be administered intravenously. Janssen’s goal is to enroll 180 people and to complete the trial in 2026. The company is also planning to recruit adolescents between the ages of 2 and 18 for a Phase II/III trial. Its goal is to enroll 12 patients. That trial is expected to be completed in 2025.

ClinicalTrials.gov lists 51 trials involving MG that are recruiting or are planning to recruit patients. While many involve a variety of therapies, others seek to identify drivers of disease progression, track the natural history of disease, determine the effect of COVID-19 vaccines on MG patients, or understand other elements of the condition.

Nipocalimab is a natural fit for Janssen, helping it accelerate the development of therapies for a variety of conditions driven by autoantibodies. Approximately 2.5% of the world’s population – approximately 195 million people – are affected by such diseases. Most often these are rare or orphan diseases.

The drug came to Janssen through the 2020 acquisition of Momenta Pharmaceuticals by Janssen’s parent company, Johnson & Johnson. Nipocalimab holds Orphan Drug designation as well as Rare Pediatric Disease designation from the U.S. Food and Drug Administration for the prevention of hemolytic disease of the fetus and newborn (HDFN).  

“We’ve been working in neuroscience for more than 60 years, and Janssen has a very strong portfolio in immunology,” Elwood said. “We have a strong commitment and significant research, as well as commercialized products in neuroscience, so nipocalimab sits in that sweet spot. This is a natural extension of our long-term commitment in neuroscience.”

For patients, the implications of finally having an effective therapy could be profound, she said. “Having a potential treatment with rapid onset that significantly reduces the autoantibodies that are driving their disease, and that offers sustained efficacy, will have a significant impact on patients’ quality of life and their disease progression.”

 

June 20, 2022/by BioSpace
Tags: autoantibody-driven disease, clinical trials, Janssen, myasthenia gravis, nipocalimab, Phase III trial
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://www.pharmalive.com/wp-content/uploads/2020/12/Can-Janssen-Cure-Cancer-Its-80-ASH-Presentations-Suggest-It’s-On-the-Right-Track-BioSpace-12-4-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-06-20 07:00:572022-06-20 11:53:47Janssen recruiting for Phase III trials of potential myasthenia gravis game changer
You might also like
Aldeyra prepares to submit dry eye disease treatment to FDA
GSK closer to cracking elusive vaccine for common respiratory virus
Sander Flaum Putting the brakes on accelerated approval won’t improve healthcare
Biohaven's drug for neurological disease fails late-stage study
FDA U.S. drug regulator lifts clinical hold on Ocugen's COVID vaccine trial
Following disappointing trial and assessment, Genocea shutters its doors
Quintiles Unveils New Predictive and Advanced Analytics Capabilities to Enhance its Risk-Based Monitoring Solution
Pharma annual report: brand values surge
Recent
  • Revolutionizing the Clinical Research Ecosystem with AI...June 27, 2022 - 5:36 pm
  • GUIDEMARK HEALTH AND CYAN HEALTH ARE NOW LUMANITYJune 27, 2022 - 4:40 pm
  • U.S. Supreme Court sides with doctors challenging opioid...June 27, 2022 - 10:58 am
  • Ipsen snags Epizyme and cancer portfolio for a cool $247...June 27, 2022 - 10:41 am
Popular
  • Revolutionizing the Clinical Research Ecosystem with AI...June 27, 2022 - 5:36 pm
  • M&A, Partnerships And CollaborationsJanuary 1, 2011 - 1:48 pm
  • OTC Review And OutlookMarch 9, 2011 - 4:17 pm
  • Global Contract Manufacturing Companies: Pharmaceutical...November 11, 2011 - 3:31 pm
Tags
Abbott AstraZeneca BioNTech Bristol-Myers Squibb Business cancer clinical trials Coronavirus Disease (COVID-19) Pandemic Covid-19 COVID-19 pandemic COVID-19 vaccines Data FDA FDA/Regulatory FDA approval featured healthcare advertising agencies healthcare communications Healthcare Communications Agencies Johnson & Johnson Moderna monkeypox mRNA-1273/Moderna COVID-19 Vaccine mRNA vaccines Novartis Omicron subvariants Omicron variant Oncology Outbreaks pediatric vaccines people on the move Personnel Appointments Pfizer Public health public health authorities public health emergencies R&D rare disease Roche Sanofi U.S. Food and Drug Administration (FDA) Vaccines WHO World Health Organization zoonotic diseases
© Copyright - PharmaLive and Outcomes LLC | Designed by Joe Lumi LLC
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
Russia accuses G20 members of politicizing health talks after criticism over... AbbVie’s Skyrizi becomes first FDA-approved IL-23 inhibitor for Crohn’s...
Scroll to top
Posting....